Pfizer Vows Appeal After India Revokes Sutent Patent
Pfizer said it plans to appeal the IPO's ruling before the Intellectual Property Appellate Board. The drugmaker also joined other pharmaceutical company's who have questioned whether India's patent system does enough to protect intellectual property rights.
“We believe the decision undermines intellectual property rights...
To view the full article, register now.